VIBRATO's Symphony: Orchestrating Biomarker Harmony for Ritlecitinib in UC Therapy

Bram Verstockt^{1

2}

Affiliations

¹ University Hospitals Leuven, Department of Gastroenterology and Hepatology, KU Leuven, Leuven, Belgium.
² KU Leuven, Department of Chronic Diseases and Metabolism, Leuven, Belgium.

Editorial

Bram Verstockt. J Crohns Colitis. 2024.

. 2024 Sep 3;18(9):1359-1360.

doi: 10.1093/ecco-jcc/jjae103.

Bram Verstockt^{1

2}

¹ University Hospitals Leuven, Department of Gastroenterology and Hepatology, KU Leuven, Leuven, Belgium.
² KU Leuven, Department of Chronic Diseases and Metabolism, Leuven, Belgium.

No abstract available

Comment on

Baseline Serum and Stool Microbiome Biomarkers Predict Clinical Efficacy and Tissue Molecular Response After Ritlecitinib Induction Therapy in Ulcerative Colitis.
Hassan-Zahraee M, Ye Z, Xi L, Dushin E, Lee J, Romatowski J, Leszczyszyn J, Danese S, Sandborn WJ, Banfield C, Gale JD, Peeva E, Longman RS, Hyde CL, Hung KE. Hassan-Zahraee M, et al. J Crohns Colitis. 2024 Sep 3;18(9):1361-1370. doi: 10.1093/ecco-jcc/jjad213. J Crohns Colitis. 2024. PMID: 38141256 Free PMC article. Clinical Trial.